Quarterly ResultMay 14, 2026, 04:16 PM
CapsoVision Q1 Revenue $2.8M; Net Loss $(7.0M); $14M Private Placement
AI Summary
CapsoVision reported stable first-quarter 2026 revenue of $2.8 million, consistent with the prior year, but experienced an increased net loss of $(7.0) million. The company secured key customer renewals and saw growing adoption of CapsoCam Plus®. Significant pipeline progress includes anticipated mid-year FDA clearance for its AI-assisted reading feature and initiation of a clinical study for CapsoCam UGI. Additionally, CapsoVision completed a $14 million private placement financing.
Key Highlights
- Completed $14 million private placement financing on March 16, 2026.
- Q1 2026 revenue was $2.8 million, stable compared to Q1 2025.
- Net loss for Q1 2026 increased to $(7.0) million from $(5.4) million in Q1 2025.
- Gross profit decreased 11% to $1.3 million, with gross margin at 48%.
- Operating expenses rose to $8.4 million, up $1.5 million from Q1 2025.
- Cash and cash equivalents totaled $17.9 million as of March 31, 2026.
- AI-assisted reading feature for CapsoCam Plus® on track for mid-year FDA clearance.
- Second-generation CapsoCam Colon 510(k) submission expected Q3 2026.